HEIDELBERG PHARMA AG O.N./ DE000A11QVV0 /
4/26/2024 6:01:31 PM | Chg. +0.04 | Volume | Bid8:48:44 PM | Ask8:48:44 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
2.98EUR | +1.36% | 1,431 Turnover: 4,303.54 |
2.91Bid Size: 2,000 | 3.07Ask Size: 684 | 101.5 mill.EUR | 0.00% | - |
GlobeNewswire
11/16/2017
Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%
GlobeNewswire
11/12/2007
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
11/12/2007
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2/5/2007
Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis
GlobeNewswire
10/9/2006
Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients